MedTrace Logo

Personalising Anti-TNF Therapy in Crohns Disease (PANTS)

NCT03088449 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 1750

Last updated 2018-06-21

No results posted yet for this study

Summary

To develop a cost-effective, individualised anti-TNF treatment strategy for patients with Crohn's disease which maximizes benefit and minimises harm.

The primary objective of this study is to investigate the mechanisms that underlie primary non-response (PNR), loss of response (LOR) and adverse drug reactions (ADRs) to anti-TNF drugs in patients with active luminal Crohn's disease.

Conditions

  • Crohn Disease

Sponsors & Collaborators

  • Merck Sharp & Dohme LLC

    collaborator INDUSTRY

  • AbbVie

    collaborator INDUSTRY

  • Pfizer

    collaborator INDUSTRY

  • Centre for Ocular Research & Education, Canada

    collaborator OTHER

  • Napp Pharmaceuticals Limited

    collaborator INDUSTRY

  • Royal Devon and Exeter NHS Foundation Trust

    lead OTHER

Principal Investigators

  • Tariq Dr Ahmad · Royal Devon and Exeter Hospital NHS Trust

Eligibility

Min Age
6 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-03-31
Primary Completion
2017-07-30
Completion
2019-07-30

Countries

  • United Kingdom

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03088449 on ClinicalTrials.gov